Details of the Drug

General Information of Drug (ID: DMW83TP)

Drug Name

Pimozide

Synonyms

Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2]

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

461.5

Topological Polar Surface Area (xlogp)

6.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 29 +/-10 hours [4]
Metabolism: The drug is metabolized via the liver [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3095 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.008 mg/mL [3]

Chemical Identifiers

Formula: C28H29F2N3O
IUPAC Name: 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
Canonical SMILES: C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
InChI: InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
InChIKey: YVUQSNJEYSNKRX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 16362
ChEBI ID: CHEBI:8212
CAS Number: 2062-78-4
DrugBank ID: DB01100
TTD ID: D00KHM
VARIDT ID: DR00484
INTEDE ID: DR1291
ACDINA ID: D00532

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[7], [8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Pimozide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Pimozide and Quetiapine.	Schizophrenia [6A20]	[67]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Pimozide and Aripiprazole.	Schizophrenia [6A20]	[68]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Pimozide and Iloperidone.	Schizophrenia [6A20]	[67]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Pimozide and Paliperidone.	Schizophrenia [6A20]	[67]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Pimozide and Molindone.	Schizophrenia [6A20]	[68]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Pimozide and Amisulpride.	Schizophrenia [6A20]	[67]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Pimozide and Asenapine.	Schizophrenia [6A20]	[67]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pimozide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Pimozide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[67]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Pimozide and Midostaurin.	Acute myeloid leukaemia [2A60]	[67]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Pimozide and Idarubicin.	Acute myeloid leukaemia [2A60]	[67]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Pimozide and Arn-509.	Acute myeloid leukaemia [2A60]	[67]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Pimozide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[67]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Pimozide and Oliceridine.	Acute pain [MG31]	[67]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Pimozide and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[69]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Pimozide and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[69]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Ivabradine.	Angina pectoris [BA40]	[67]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Pimozide and Bepridil.	Angina pectoris [BA40]	[67]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Pimozide and Dronedarone.	Angina pectoris [BA40]	[70]
Nifedipine	DMSVOZT	Major	Decreased metabolism of Pimozide caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[71]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Pimozide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[67]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Pimozide and Cilostazol.	Arterial occlusive disease [BD40]	[67]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Pimozide caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[71]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Pimozide and Levalbuterol.	Asthma [CA23]	[72]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Pimozide and Pirbuterol.	Asthma [CA23]	[73]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Pimozide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[67]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Pimozide caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[74]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Pimozide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[67]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Pimozide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[75]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Pimozide caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[76]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Pimozide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[67]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Pimozide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[67]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Pimozide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[67]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Pimozide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[76]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Pimozide and Retigabine.	Behcet disease [4A62]	[67]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Pimozide and Cariprazine.	Bipolar disorder [6A60]	[68]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Pimozide caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[77]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Pimozide and Eribulin.	Breast cancer [2C60-2C6Y]	[67]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Pimozide caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[71]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Pimozide and Bosutinib.	Breast cancer [2C60-2C6Y]	[67]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Pimozide when combined with Acetylcholine.	Cataract [9B10]	[78]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Pimozide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[67]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Pimozide and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[79]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Pimozide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[73]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Pimozide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[72]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Pimozide and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[79]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Pimozide and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[79]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Pimozide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[73]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Pimozide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[73]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Pimozide and Dihydrocodeine.	Chronic pain [MG30]	[80]
Panitumumab	DMQPD1F	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Panitumumab.	Colorectal cancer [2B91]	[81]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Pimozide and Halothane.	Corneal disease [9A76-9A78]	[67]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Pimozide and Sevoflurane.	Corneal disease [9A76-9A78]	[67]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Pimozide and Probucol.	Coronary atherosclerosis [BA80]	[67]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Pimozide and Pasireotide.	Cushing syndrome [5A70]	[67]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Pimozide and Osilodrostat.	Cushing syndrome [5A70]	[67]
MK-8228	DMOB58Q	Major	Decreased metabolism of Pimozide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[71]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Pimozide and Sertraline.	Depression [6A70-6A7Z]	[82]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Pimozide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Pimozide and Escitalopram.	Depression [6A70-6A7Z]	[70]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Pimozide and OPC-34712.	Depression [6A70-6A7Z]	[68]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Pimozide and Clomipramine.	Depression [6A70-6A7Z]	[67]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Pimozide and Doxepin.	Depression [6A70-6A7Z]	[67]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Pimozide and Esketamine.	Depression [6A70-6A7Z]	[71]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Pimozide and Mepenzolate.	Digestive system disease [DE2Z]	[68]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Pimozide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[67]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Pimozide and Deutetrabenazine.	Dystonic disorder [8A02]	[67]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Pimozide and Ingrezza.	Dystonic disorder [8A02]	[67]
Stiripentol	DMMSDOY	Major	Decreased metabolism of Pimozide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[71]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Pimozide caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[67]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Pimozide and Solifenacin.	Functional bladder disorder [GC50]	[67]
Mirabegron	DMS1GYT	Major	Decreased metabolism of Pimozide caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[70]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Pimozide caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[71]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Pimozide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[83]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Pimozide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[67]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Dichlorphenamide.	Glaucoma [9C61]	[83]
Telaprevir	DMMRV29	Major	Decreased metabolism of Pimozide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[71]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Pimozide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[84]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Pimozide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[71]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Pimozide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Saquinavir	DMG814N	Major	Decreased metabolism of Pimozide caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[71]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Pimozide caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[85]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Pimozide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Darunavir	DMN3GCH	Major	Decreased metabolism of Pimozide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[71]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Pimozide caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[71]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Pimozide and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[68]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Pimozide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[86]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Pimozide and ITI-007.	Insomnia [7A00-7A0Z]	[68]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[87]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Pimozide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[70]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Pimozide caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[67]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Pimozide and Crizotinib.	Lung cancer [2C25]	[67]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Pimozide caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[88]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Pimozide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[89]
Dacomitinib	DMOH8VY	Major	Decreased metabolism of Pimozide caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[70]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Pimozide and Osimertinib.	Lung cancer [2C25]	[67]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Pimozide and Selpercatinib.	Lung cancer [2C25]	[67]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Pimozide and Halofantrine.	Malaria [1F40-1F45]	[90]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Pimozide and Hydroxychloroquine.	Malaria [1F40-1F45]	[67]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Pimozide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[67]
Idelalisib	DM602WT	Major	Decreased metabolism of Pimozide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[71]
IPI-145	DMWA24P	Major	Decreased metabolism of Pimozide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[71]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Pimozide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[67]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Pimozide and Vemurafenib.	Melanoma [2C30]	[67]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Pimozide and LGX818.	Melanoma [2C30]	[67]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Pimozide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[67]
Danazol	DML8KTN	Major	Decreased metabolism of Pimozide caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[71]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Pimozide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[91]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Pimozide and Lasmiditan.	Migraine [8A80]	[92]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Pimozide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[93]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Pimozide and Flibanserin.	Mood disorder [6A60-6E23]	[94]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Pimozide and Panobinostat.	Multiple myeloma [2A83]	[67]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Fingolimod.	Multiple sclerosis [8A40]	[70]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Pimozide and Ozanimod.	Multiple sclerosis [8A40]	[67]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Pimozide and Romidepsin.	Mycosis fungoides [2B01]	[67]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Pimozide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[71]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Pimozide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[67]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Pimozide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[67]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Pimozide and Phenindamine.	Nasopharyngitis [CA00]	[68]
Rolapitant	DM8XP26	Major	Decreased metabolism of Pimozide caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[70]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Pimozide and Cyclizine.	Nausea/vomiting [MD90]	[68]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Pimozide and Metoclopramide.	Nausea/vomiting [MD90]	[95]
Bupropion	DM5PCS7	Major	Decreased metabolism of Pimozide caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[70]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Pimozide and Entrectinib.	Non-small cell lung cancer [2C25]	[67]
Lorcaserin	DMG6OYJ	Major	Decreased metabolism of Pimozide caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[70]
Polythiazide	DMCH80F	Major	Increased risk of ventricular arrhythmias by the combination of Pimozide and Polythiazide.	Oedema [MG29]	[81]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Pimozide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[67]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Pimozide and Lofexidine.	Opioid use disorder [6C43]	[67]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Pimozide due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[71]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Pimozide and Rucaparib.	Ovarian cancer [2C73]	[67]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Pimozide and Oxymorphone.	Pain [MG30-MG3Z]	[96]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Pimozide and Dezocine.	Pain [MG30-MG3Z]	[96]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Pimozide and Flavoxate.	Pain [MG30-MG3Z]	[68]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Pimozide and Triclabendazole.	Parasitic worm infestation [1F90]	[67]
Pergolide	DM14MAE	Moderate	Additive CNS depression effects by the combination of Pimozide and Pergolide.	Parkinsonism [8A00]	[97]
Opicapone	DM1BKA6	Moderate	Additive CNS depression effects by the combination of Pimozide and Opicapone.	Parkinsonism [8A00]	[97]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Pimozide when combined with Levodopa.	Parkinsonism [8A00]	[97]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Pimozide and Pimavanserin.	Parkinsonism [8A00]	[67]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Pimozide when combined with Bromocriptine.	Parkinsonism [8A00]	[97]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Pimozide and Orphenadrine.	Parkinsonism [8A00]	[68]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Pimozide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[98]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Pimozide and Methylscopolamine.	Peptic ulcer [DA61]	[68]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Pimozide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[99]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Pimozide and Lefamulin.	Pneumonia [CA40]	[67]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Pimozide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[71]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Pimozide and Degarelix.	Prostate cancer [2C82]	[67]
ABIRATERONE	DM8V75C	Major	Decreased metabolism of Pimozide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[70]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Pimozide and Enzalutamide.	Prostate cancer [2C82]	[67]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Pimozide and Relugolix.	Prostate cancer [2C82]	[67]
Bicalutamide	DMZMSPF	Major	Decreased metabolism of Pimozide caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[71]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Pimozide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[67]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Pimozide when combined with Neupro.	Restless legs syndrome [7A80]	[97]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Pimozide caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[71]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Pimozide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[71]
Armodafinil	DMGB035	Minor	Increased metabolism of Pimozide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[100]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Pimozide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[67]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Pimozide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[67]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Pimozide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[67]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Pimozide and Pitolisant.	Somnolence [MG42]	[67]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Pimozide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[67]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Pimozide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[101]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Pimozide caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[67]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Pimozide and Lenvatinib.	Thyroid cancer [2D10]	[67]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Pimozide and Cabozantinib.	Thyroid cancer [2D10]	[67]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Pimozide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[67]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Pimozide and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[68]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Pimozide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[67]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Pimozide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[67]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Pimozide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[67]
-----------


⏷ Show the Full List of 161 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Pimozide 1 mg tablet	1 mg	Oral Tablet	Oral
Pimozide 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 90).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017473.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
8	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
9	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
11	The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
12	Drug Interactions Flockhart Table
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
32	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
33	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
34	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
35	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
36	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
37	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
38	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
39	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
40	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
41	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
42	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
48	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
50	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
51	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
52	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
53	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
54	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
55	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
56	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
57	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
58	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
59	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
60	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
61	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
62	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
63	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
64	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
65	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
66	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
67	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
69	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
70	Canadian Pharmacists Association.
71	Cerner Multum, Inc. "Australian Product Information.".
72	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
73	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
74	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
75	Flockhart DA, Drici MD, Kerbusch T, et al "Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome." J Clin Psychopharmacol 20 (2000): 317-24. [PMID: 10831018]
76	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
77	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
78	Multum Information Services, Inc. Expert Review Panel.
79	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
80	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
81	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
82	Alderman J "Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers." Clin Ther 27 (2005): 1050-63. [PMID: 16154484]
83	Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
84	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
85	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
86	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
87	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
88	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
89	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
90	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
91	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
92	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
93	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
94	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
95	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
96	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
97	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
98	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
99	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
100	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
101	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.